Publications by authors named "H Otaka"
Article Synopsis
- Fabry disease is a rare metabolic disorder caused by low levels of alpha-galactosidase A, leading to the build-up of a certain fat (Gb3) and affecting multiple organ systems.
- A long-term study of agalsidase alfa, a treatment approved in Japan, showed it was effective and well-tolerated over a 6.5-year extension period, after an initial 8-year post-marketing surveillance.
- The study noted a decrease in serious adverse events among male patients over time, but female patients continued to experience higher rates of cardiac complications; overall, the treatment maintained its efficacy and safety profile.*
Introduction: Progressive multifocal leukoencephalopathy (PML) is an infrequent yet devastating neurological infection that arises in immunocompromised patients. The epidemiological features of PML in Japan and its evolution in recent years remain unclear. There are no established treatments that directly target PML.
View Article and Find Full Text PDFIntroduction: The healthcare situation of multiple sclerosis (MS) and its course are not being thoroughly investigated in Japan. We aimed to examine the current healthcare situation, including treatment and healthcare costs, of MS according to duration since its first diagnosis using Japanese real-world data to determine unidentified healthcare issues at each disease stage.
Methods: This retrospective, non-comparative, non-interventional study used a Japanese nationwide claims database (April 2008-August 2018) comprising 20 million patients from 329 acute care hospitals (as of June 2018).
Background: Growing evidence indicates that carefully programmed rehabilitation can improve symptoms in patients with myasthenia gravis (MG). However, evidence on rehabilitation to aid in recovery from a myasthenic crisis is lacking. This study aimed to examine the association between inpatient rehabilitation and recovery in the activities of daily living (ADL) after a myasthenic crisis.
View Article and Find Full Text PDFArticle Synopsis
- Japanese claims databases are useful for researching multiple sclerosis (MS), but they lack information on disease severity and disability.
- The study developed a MS severity score using principal component analysis (PCA), analyzing data from 7067 MS patients and correlating this score with factors like age, gender, and disease duration.
- The findings suggest that the new PC1 score aligns with previous research on MS severity, but more validation is needed using clinical measures like the Expanded Disability Status Scale (EDSS).